GSK Flixotide Nebules launched in mainland China for acute exacerbations of childhood asthma

GSK announced today that Flixotide Nebules (generic name: Fluticasone Propionate Nebuliser Suspension) was officially launched in mainland China and provides a new option for the treatment of childhood asthma.

GSK announced today that Flixotide Nebules (generic name: Fluticasone Propionate Nebuliser Suspension) was officially launched in mainland China and provides a new option for the treatment of childhood asthma.

Flixotide Nebules is indicated for the treatment of mild-to-moderate acute asthma attack in children and adolescents aged 4-16 years in the market. It can significantly improve pulmonary function and relieve acute symptoms through continuous strong anti-inflammatory effect, which may reduce the possibility of hospitalisation.

Professor Chuanhe Liu from the Children’s Hospital of Capital Institute of Pediatrics said, “Childhood asthma incidence is on the rise recently in China. Many children were hospitalised due to acute attack, which not only increased the disease burden for their families, but also increased the chances of absence of class and work for patients and their parents. Therefore, it’s medically important and critical to prevent and adequately manage asthma and exacerbations in children. The launch of Flixotide Nebules provides a new option for the treatment of acute attack of childhood asthma. It can help relieve the acute symptoms effectively in asthma children, reduce the use of systemic corticosteriods as well as the possibility of hospitalisation. “ 

Although the diagnosis rate of childhood asthma has improved over the past ten years in China, about 80% of the patients have experienced acute attack during the past 12 months, among whom 50% received hospitalisation[1]

Dr. James He, VP and Country Medical Director for GSK China said: “Flixotide Aerosol was launched in China in 2000, fluticasone propionate has strong anti-inflammatory effect to relieve the acute symptoms in childhood asthma. GSK has extensive experience in chronic airway disease globally, including asthma. Our goal at GSK is to provide physicians with an expanded range of childhood asthma medicines which enable a patient-centric approach to treatment, as recommended by asthma guidelines.”   

Global Initiative for Asthma (GINA) 2018 states that high doses of inhaled corticosteroid (ICS) can relieve symptoms and reduce systemic corticosteriods during acute attacks of asthma[2]. ICS is also recommended as the first-line therapy for acute attack of childhood asthma in Chinese guidelines for childhood asthma 2016[3].

GSK is committed to enhancing the healthcare capabilities in asthma management and helping Chinese patients to improve their conditions and quality of life. Since 2016, GSK has partnered with China Association of Health Promotion and Education to support the establishment of "Asthma Clinic" in 20 hospitals in four provinces, having benefited more than 8,000 asthma patients as of end 2017. In 2017, GSK supported Guangzhou Institute of Respiratory Disease to launch “New Respiration and Frequent Care” online management platform in order to improve China’s asthma control level. In the near future, GSK will also introduce more innovative and advanced medicines and solutions to provide individualised treatment for patients with chronic airway diseases in China.


GSK in China with China for China

GSK is committed to supporting the healthcare reform of the Chinese government and to ensuring that Chinese patients can access our innovative treatments targeting their specific needs. As part of our strategy to be "in China, with China, for China", we have achieved the following milestones in recent years:

  • The Chinese Association of STD and AIDS Prevention and Control and GSK China sign MOU for AIDS prevention and control through online physician education in May 2018.
  • GSK China partners with JD to drive “Internet + Healthcare” to improve patient experience and access to healthcare in May 2018.
  • Anoro Ellipta, a new once-daily dual bronchodilators treatment for COPD, was approved in March 2018.
  • Our innovative antiretroviral Single Tablet Regimen (STR) Triumeq was officially launched in January 2018.
  • Supported the launch of “New Respiration and Frequent Care” online management platform for asthma patients in December 2017.
  • Supported the launch of the UK-China Health and Economy Partnership in November 2017.
  • Supported the launch of "Happy Breath" COPD Tiered Diagnosis and Treatment Project across China in November 2017.
  • Flixotide Nebules received approval for the treatment of children asthma in September 2017.
  • Announced partnership with Ali Health to launch innovative online service platform to improve adult vaccination consultation experience in August 2017.
  • Innovative antiretroviral Single Tablet Regimen (STR) Triumeq received approval in China in August 2017.
  • Cervarix, the first vaccine for cervical cancer prevention in mainland China, was officially launched in July 2017.
  • Announced collaboration programme to aid hepatitis prevention and treatment in poverty-stricken areas of the western region in July 2017.
  • Seroxat CR and Tykerb were included into the list of reimbursed drugs as results of the national health insurance negotiations in July 2017.
  • Announced a strategic partnership with academia to co-develop health big-data system and upgrade the management of respiratory diseases in June 2017.
  • Aided the National Preventive Vaccination Services and Management Training Programme, helmed by the Chinese Preventive Medicine Association under the guidance of the National Health and Family Planning Commission, with the support of the China Centre for Disease Control and Prevention that officially kicked off in June 2017.
  • Viread, Arixtra, Requip and Mivacron were included in the “2017 National Reimbursement Drug List” in March 2017.


GSK – a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit


GSK media enquiries:

Chloe Yao            (China)

Susan Song         (China)


Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Principal risks and uncertainties' in the company's Annual Report on Form 20-F for 2016.



[1] Li SHA, Chuanhe LIU, Mingjun SHAO, et al. Chinese Journal of Pediatrics 2016: 54; 182-186

[2] Global Initiative for Asthma (2018 update)

[3] Respiratory group, Pediatrics branch of Chinese Medical Association. Chinese Journal of Pediatrics. Guideline on diagnosis and prevention of bronchial asthma in children (2016). 2016;54(3):167-181.